More than 38 million people in the U.S. are living with diabetes.

A Delhi HC directive to examine unregulated use of weight loss drugs may lead to a CDSCO expert panel by mid-July, possibly ...

The country’s Medicines and Healthcare products Regulatory Agency’s (MHRA) Yellow Card scheme, the UK’s official system for ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Health insurance companies, including CVS Caremark, are altering coverage for GLP-1 weight loss medications like Zepbound, ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Obesity is a common risk factor for several serious health conditions like diabetes, heart disease, hypertension, fatty liver ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

A report from the human resources trade group SHRM, which just released its 2025 Benefits Survey—the most comprehensive ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.